Hepatocellular Carcinoma Excellence Forum

Leaders in the field sharing authoritative insights and institutional best practices.
Featured
Ghassan Abou-Alfa, MD, discusses integrating novel agents into treatment of hepatocellular carcinoma at the virtual 2020 ESMO World GI meeting.
View More
Ghassan Abou-Alfa, MD, discusses systemic and local therapy updates in hepatocellular carcinoma in the third part of this interview highlighting abstracts of note presented at the virtual 2020 ASCO…
View More
Dr Mukherji summarizes 3 posters that were presented at the virtual ESMO World Congress on GI Cancer, which identify gaps in research and can inform future biliary tract cancer trials.
View More
Dr Abou-Alfa discusses novel therapies and why etiology is important in the treatment of hepatocellular carcinoma in the second part of this interview highlighting abstracts of note presented at the…
View More
Ghassan Abou-Alfa, MD, discusses the clinical value of certain combo therapy regimens for patients with unresectable HCC.
View More
Ghassan Abou-Alfa, MD; Arndt Vogel, MD, PhD; and Chris Verslype, MD, PhD, FACP, discuss the significance of the REACH and REACH-2 trials.
View More
At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Bekaii-Saab discussed the role of cabozantinib in the second-line HCC therapy.
View More
At the 2019 Great Debates & Updates in GI Malignancies meeting, Dr Bekaii-Saab discussed how to best sequence drugs in the treatment of HCC.
View More
Stay in the know.
OncNet Newsletter